A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

Item
http://www.wikidata.org/entity/Q38881093
XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose.Treatment of relapsed/refractory acute myeloid leukaemia in adults.Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.Karyopherins in cancer.Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.Nuclear Export Inhibition for Pancreatic Cancer Therapy.Decrease of 5-hydroxymethylcytosine and TET1 with nuclear exclusion of TET2 in small intestinal neuroendocrine tumorsNuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectivesPhase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
P2860

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

Item
http://www.wikidata.org/entity/Q38881093
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
@en
type
label
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
@en
prefLabel
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia
@en
P2093
P2860
P304
P31
P356
10.1182/BLOOD-2016-11-750158
P407
P433
P478
P50
P577
P698
P921
P932